Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-32Oncolytic virus therapy for prostate cancer
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-84Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-10-01 / Melanoma Res. 2009 Oct;19(5):309-15Immunizing against breast cancer: a new swing for an old sword
/in Breast Cancer, Dendritic Cells, International Publications /von 2009-10-01 / Breast 2009 Oct;18 Suppl 3:S51-4Dendritic cell therapy of high-grade gliomas
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712Immunotherapy of diffuse gliomas: biological background, current status and future developments
/in Glioblastoma, International Publications /von 2009-10-01 / Brain Pathol. 2009 Oct;19(4):674-93An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
/in Glioblastoma, International Publications /von 2009-10-01 / Mol. Cancer Ther. 2009 Oct;8(10):2773-9Dendritic cell-based cancer gene therapy
/in Dendritic Cells, International Publications /von 2009-10-01 / Hum. Gene Ther. 2009 Oct;20(10):1106-18
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution